A Study of ICP-022 in Patients With R/R DLBCL
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There will be no control group in this study. Each subject will receive treatment orally every day in 28-day cycles. Each cycle starts immediately after the previously completed cycle without a break between cycles.
Diffuse Large B Cell Lymphoma
DRUG: ICP-022
Overall response rate（ORR）, The efficacy measured by overall response rate (ORR) according to the 2014 International Working Group NHL, Up to 3 years
Occurrence of adverse events and serious adverse events, The safety of ICP-022 measured by the occurrence of adverse events and serious adverse events according to NCI-CTCAE 5.0 grading criteria, Up to 3 years|Progression free survival（PFS）, The efficacy measured by progression free survival（PFS）, Up to 3 years|Duration of response（DOR）, Up to 3 years
It is a phase II, multicenter, open-label study is to evaluate the safety, efficacy and pharmacokinetics of a novel BTK inhibitor, ICP-022, in approximately 85 subjects with R/R DLBCL. There will be no control group in this study. Each subject will receive treatment orally every day in 28-day cycles. Each cycle starts immediately after the previously completed cycle without a break between cycles.